AstraZeneca's Lung Cancer Trial Shows Survival Improvement
May 07 2021 - 02:48AM
Dow Jones News
By Sabela Ojea
AstraZeneca PLC said Friday that the combination of its Imfinzi
drug and tremelimumab with chemotherapy showed an overall survival
benefit in its metastatic non-small cell lung cancer Phase 3
Poseidon trial.
The pharmaceutical company added that the use of Imfinzi with
chemotherapy didn't achieve a trend in overall survival.
"We've seen encouraging uptake of novel combinations in this
setting and believe this new approach will add a further option for
patients with high unmet medical need," said Dave Fredrickson,
executive vice president of Astrazeneca's oncology business
unit.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
May 07, 2021 02:33 ET (06:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Feb 2024 to Mar 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Mar 2023 to Mar 2024